Xeris Pharmaceuticals Awarded Phase II Funding of National Institutes of Health (NIH) Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas
4/17/2013 11:18:20 AM
Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, pharmaceutical company developing patient-friendly injectable treatments for diabetes and other diseases, has been awarded the Phase II installment of a Small Business Innovation Research (SBIR) Fast Track grant for $713,733. The grant, totaling $1.05 million, was awarded in 2012 to advance the company's room-temperature stable, non-aqueous glucagon formulation for the advancement of a bi-hormonal pump artificial pancreas. It comes from the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), an institute of the National Institutes of Health (NIH) that funds research on diabetes and other metabolic diseases.